SGIOF:OTC-Shionogi & Co., Ltd (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 50.23

Change

0.00 (0.00)%

Market Cap

USD 15.14B

Volume

1.45K

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment; and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. The company also offers antibody detection kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with InveniAI, LLC.; Hsiri Therapeutics Inc.; Nagasaki University; Roche Group to develop and commercialize Xofluza; and Nagasaki University and The Kitasato Institute to develop antimalarial drugs and vaccines. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-20 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKGAF MERCK Kommanditgesellschaft au..

N/A

USD80.36B 29.16 17.26
MKKGY MERCK Kommanditgesellschaft au..

N/A

USD79.39B 28.51 17.26
TKPHF Takeda Pharmaceutical Company ..

N/A

USD54.07B 15.78 0.07
ESALY Eisai Co., Ltd

N/A

USD31.03B 81.65 0.19
ESALF Eisai Co., Ltd

N/A

USD29.49B 76.17 0.19
SFOSF Shanghai Fosun Pharmaceutical ..

N/A

USD23.06B 29.29 4.17
SGIOY Shionogi & Co., Ltd

N/A

USD15.39B 15.49 0.07
TEVJF Teva Pharmaceutical Industries..

N/A

USD11.26B 900.00 16.02
BAYP Bayport International Holdings..

N/A

USD10.85B N/A N/A
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21

ETFs Containing SGIOF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.08% 24% F 20% F
Dividend Return 0.87% 26% F 18% F
Total Return -8.21% 24% F 20% F
Trailing 12 Months  
Capital Gain -22.54% 22% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.54% 22% F 11% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.45% 39% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.45% 37% F 29% F
Risk Return Profile  
Volatility (Standard Deviation) 10.91% 100% A+ 93% A
Risk Adjusted Return 13.28% 49% F 35% F
Market Capitalization 15.14B 98% A+ 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 15.25 45% F 51% F
Price/Book Ratio 2.07 54% F 47% F
Price / Cash Flow Ratio 0.14 25% F 47% F
EV/EBITDA 0.07 91% A- 83% B
Management Effectiveness  
Return on Equity 14.48% 88% B+ 82% B-
Return on Invested Capital -8.10% 55% F 28% F
Return on Assets 8.28% 94% A 92% A-
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.88 54% F 50% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.